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Abstract: Objective: Our overall goal was to investigate the anti-tumor activity of the glutaminase 1 (GLS1) Inhibitor 
compound 968 in ovarian cancer cells. The human ovarian cancer cell lines, HEY, SKOV3 and IGROV-1 were used. 
Cell proliferation was assessed by MTT assay after treatment with compound 968. Cell cycle progression and 
Annexin V expression were evaluated using Cellometer. Western blotting was performed to determine changes 
in GLS1, cellular stress and cell cycle checkpoints. Reactive oxygen species (ROS) and glutamate dehydrogenase 
(GDH) activity were assessed by ELISA assay. Compound 968 significantly inhibited cell proliferation and the expres-
sion of GLS1 in a dose-dependent manner in all three ovarian cancer cell lines. Compound 968 induced G1 phase 
cell cycle arrest and apoptosis. Treatment with compound 968 increased ROS levels and induced the protein expres-
sion of calnexin, binding immunoglobulin protein (BiP) and protein kinase RNA-like endoplasmic reticulum kinase 
(PERK). Deprivation of glutamine increased the sensitivity of cells to paclitaxel, and compound 968 sensitized cells 
to the anti-proliferative effects of paclitaxel. Compound 968 inhibited cell growth in ovarian cancer cells through 
induction of G1 phase cell cycle arrest, apoptosis and cellular stress, suggesting that targeting GLS1 provide a novel 
therapeutic strategy for ovarian cancer. 
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Introduction
Ovarian cancer is the deadliest gynecologic 
malignancy, with an estimated 22,280 cases 
and 14,240 deaths predicted for 2016 [1]. The 
majority of ovarian cancers are diagnosed at a 
late stage, largely due to non-specific symp-
toms and the lack of a reliable screening test. 
The mainstay of treatment for ovarian cancer 
is cytoreductive surgery (to a goal of no gross 
residual tumor) followed by paclitaxel and plati-
num based doublet chemotherapy. This treat-
ment strategy provides effective tumor control 
in more than 80% of patients; however, most 
patients will develop disease recurrence and 
drug resistance. Thus, new treatment options 
for ovarian cancer are urgently needed.
Glutamine is the most abundant nonessential 
amino acid. It exists in every protein in the 
human body whose primary function involves 
energy metabolism, reduction-oxidation hom- 
eostasis, macromolecule synthesis and signal-
ing [2, 3]. Although glucose is the major energy 
source to support cancer cell growth, glutamine 
contributes to oxidative phosphorylation and 
glycolysis energy-forming pathways in cancer 
cells [4]. Glutaminase is an amidohydrolase and 
rate-limiting enzyme that catalyzes the first 
step in the glutaminolysis of glutamine to gluta-
mate in reactions that either donate theamide 
nitrogen to biosynthetic pathways or release it 
as ammonia. Glutaminase exists as two iso-
forms, glutaminase 1 (GLS1) and glutaminase 
2 (GLS2), and were originally identified in the 
kidney and liver, respectively [4]. GLS1 is a 
phosphate-dependent enzyme with two major 
splice variants: a long form (KGA) and a short 
form (GAC) [5]. GLS1 is expressed in all mam-
malian tissue except for liver and is associated 
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with tumor growth and invasive activities in a 
number of cancer types [6]. Indeed, most can-
cer cells cannot survive in vitro in the absence 
of an exogenous glutamine supply, indicating 
that cancer cells are glutamine dependent [5, 
7]. Inhibition of glutaminolysis or GLS1 activity 
can induce cell apoptosis and decrease tumor 
growth in cancer cells and animal models of 
cancer [5, 6, 8, 9]. Our previous study demon-
strated that glutamine restriction results in 
inhibition of cell growth, induction of apoptosis, 
G1 phase cell cycle arrest and increased reac-
tive oxygen species (ROS) production through 
alterations in the mTOR pathway in ovarian can-
cer cells [10]. 
Compound 968 is a small molecule that acts 
as an allosteric regulator of GLS1 and inhibits 
the activity of KGA and GAC. Several groups 
have reported anti-tumor activity for compo- 
und 968 in lymphoma, breast cancer, glio- 
blastoma and lung cancer in vitro [11-15]. 
Furthermore, compound 968 has been shown 
to block oncogenic transformation induced by 
various Rho GTPases in fibroblasts, without 
toxic effects on normal cells [11, 16]. Thus, 
inhibition of GLS1 by compound 968 or other 
GLS1 inhibitors may provide a new thera- 
peutic strategy for the treatment of different 
types of cancer, including ovarian cancer. In 
the current study, we aimed to address the 
anti-tumorigenic effects and underlying mec- 
hanisms of compound 968 in ovarian cancer 
cells. 
Materials and methods 
Cell Culture and reagents 
The human ovarian cancer cell lines HEY, 
SKOV3 and IGROV-1 were used. The HEY and 
IGROV-1 cell lines were maintained in RPMI-
1640 medium supplemented with 5% and 
10% fetal bovine serum (FBS), respectively. 
The SKOV3 cell line was maintained in DMEM/
F12 medium supplemented with 10% FBS. To 
study the effects of compound 968, we used 
Gibco DMEM/F-12(1:1) medium with L-Gluta- 
mine and 15 mM Hepes (Catalog Number: 
11039), containing 5% HyClone Characteri- 
zed FBS and supplied with varying concentra-
tions of compound 968. The media was sup- 
plemented with 100 U/ml penicillin and 100 
ug/ml streptomycin. The cells were cultured in 
a humidified 5% CO2 at 37°C.
Compound 968 was purchased from Calbio- 
chem (Billerica, MA). 3-(4,5-Dimethyl-2-thiazo- 
lyl)-2, 5-diphenyl-2H-tetrazolium bromide (M- 
TT), RNase A, 2’, 7’-Dichlorofluorescin diace-
tate (DCFH-DA) and Paclitaxel were purchased 
from Sigma-Aldrich (St. Louis, MO). The GDH 
assay kit was bought from BioVision (Milpitas, 
CA). The Annexin V FITC kit was purchased 
from Biolegend (San Diego, CA). The anti-gluta-
minase (GLS1) antibody was purchased from 
Abcam (Cambridge, MA), and all the other an- 
tibodies were obtained from Cell Signaling 
(Danvers, MA). Enhanced chemiluminescence 
(ECL) detection reagents were purchased from 
GE Health care (Piscataway, NJ). All other che- 
micals were purchased from Sigma-Aldrich 
(St. Louis, MO).
Cell proliferation assay 
The ovarian cancer cell lines, HEY, SKOV3 and 
IGROV-1, were treated with media containing 
different concentrations of compound 968 (0, 
2, 5, 10, 25, 50 uM) for 5 days after seeding 
cells at 3000 cells/well in 96-well plates in 
their culture media for 5 h. The media was 
refreshed at day 3. Cell proliferation was mea-
sured by adding 5 ul MTT solution (5 mg/ml) 
per well for an additional incubation time of 1 h. 
The MTT reaction was terminated through the 
replacement of the media by 100 ul DMSO. 
Viable cell densities were determined by mea-
suring absorbance of metabolic conversion of 
the colorimetric dye at 570 nm. Each experi-
ment was performed in triplicate and repeated 
three times to assess for consistency of results. 
Cell cycle analysis 
The effect of compound 968 on cell cycle 
progression was assessed using Cellometer 
(Nexcelom, Lawrence, MA). Cells were plated at 
a density of 1.5 × 105 cells/well in 6-well plates 
for 5 h, and then treated with varying concen-
trations of compound 968 (0, 5, 10, 25 uM) for 
48 h. Cells were collected by 0.05% trypsin 
(Gibco Grand Island, NY), washed with phos-
phate-buffered saline (PBS) solution, fixed in a 
90% methanol solution and then stored at 
-20°C until cell cycle analysis was performed. 
On the day of analysis, the cells were washed 
with PBS and centrifuged, resuspended in 50 
ul RNase A solution (250 ug/ml) with 10 mM 
EDTA, followed by incubation for 30 min at 
37°C. After incubation, 50 µl propidium iodide 
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(PI) staining solution (2 mg/ml PI, 0.1 mg/ml 
Azide and 0.05% Triton X-100) was added to 
each tube and incubated for 10 min in the dark. 
The cells were assessed by Cellometer. The 
results were analyzed using FCS4 express 
software (Molecular Devices, Sunnyvale, CA). 
Each experiment was repeated at least twice 
for consistency of response. 
Annexin V assay
The effect of compound 968 on cell apoptosis 
was detected by using the Annexin-V FITC kit. 
Briefly, 1.75 × 105 cells/well were seeded into 
6-well plates for 5 h, and then the cells were 
treated with different concentrations of com-
pound 968 (0, 5, 10, 25 uM) for 24 h. The cells 
were collected by 0.25% trypsin without EDTA. 
After washing with PBS, cells were resuspend-
ed in 100 ul Annexin-V and PI dual-stain solu-
tion (0.1 ug Annexin-V FITC and 1 ug PI) for 15 
min in the dark and detected by Cellometer. 
The results were analyzed by FCS4 express 
software. Each experiment was repeated at 
least twice for consistency of response. 
Reactive oxygen species (ROS) assay
Intracellular reactive oxygen species (ROS) pro-
duction was detected using DCFH-DA. After 
treatment of the cells with different concentra-
tions of compound 968 for 24 h, 10 ul of 200 
uM DCFH-DA was added into the media and 
mixed gently. The fluorescence intensity was 
measured at an excitation wavelength of 485 
nm and an emission wavelength of 530 nm 
using a plate reader (Tecan, Morrisville, NC). 
Data were normalized based on the viable cell 
counts measured by the MTT assays. Each 
experiment was performed in triplicate and 
repeated three times for consistency of results.
Glutamate dehydrogenase (GDH) activity assay 
Intracellular GDH activity was measured by 
using the GDH assay kit. HEY cells were trea- 
ted with compound 968 for 24 h. Cell lysates 
were prepared in cold GDH lysis buffer. Ten 
to 20 ul of cell lysates were transferred into a 
new 96-well plate, then GDH assay buffer was 
added until the total volume was 50 ul. Next, 
100 ul of reaction mix (82 ul GDH assay buffer, 
8 ul GDH developer and 10 ul glutameate) was 
added to each well. The concentration of GDH 
was measured at wavelength of 450 nm in a 
plate reader after incubating for 3 min at 37°C. 
The results were normalized on the basis of 
the total protein concentration of each sample. 
The experiment was performed in triplicate 
and repeated twice to assess for consistency 
of results. 
Western blot analysis
Total protein was extracted from ovarian can-
cer cells using RIPA buffer (Boston Bioproducts, 
Ashland, MA), and the protein was quantified 
with the BCA assay kit (Thermo Scientific, 
Rockford, IL). Protein samples with equal load-
ing (30 ug) were separated by 10-12% SDS-
PAGE and transferred onto polyvinylidene 
fluoride (PVDF) membranes. The membranes 
were blocked with 5% nonfat milk and then 
incubated with a 1:1000 dilution of primary 
antibodies for overnight at 4°C. The membra- 
nes were washed and incubated with a sec- 
ondary peroxidase-conjugated antibody for 
1 h at room temperature. The membranes 
were developed using enhanced ECL at Alpha 
Innotech Imaging System (Protein Simple, 
Santa Clara, CA). After developing, the mem-
branes were re-probed using an antibody 
against α-tubulin to confirm equal loading. The 
bands’ intensity were measured and normal-
ized to α-tubulin. Each experiment was repe- 
ated at least twice for consistency of results. 
Statistical analysis
Data are expressed as mean ± standard error. 
Data were compared using the two-tailed 
Student’s t test with P<0.05 considered sta- 
tistically significant. Analysis of synergy was 
calculated using CalcuSyn software (Biosoft, 
Cambridge, UK). Combination index (CI)<1 indi-
cates synergism, CI=1 indicates additive eff- 
ects and CI>1 indicates antagonism. 
Result
Compound 968 inhibited ovarian cancer cells 
proliferation
To investigate the inhibitory effects of com-
pound 968 on cell growth in ovarian cancer 
cell lines, we treated three ovarian cancer cell 
lines (HEY, SKOV3, IGROV-1) with compound 
968 for 5 days. Our results indicate that 
compound 968 inhibited proliferation in all 
three cell lines in a dose-dependent manner 
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(Figure 1A). Furthermore, all cell lines were 
inhibited with a concentration of compound 
968 as low as 2 uM. The half maxi-
mal inhibitory concentrations (IC 
50) were 8.9 ± 1.1 uM, 29.1 ± 4.1 
uM and 3.5 ± 1.15 uM for HEY, 
SKOV3 and IGROV-1, respectively. 
We tested the effect of compound 
968 on the expression of GLS1 
after 24 h of treatment. The GLS1 
antibody recognizes two isoen-
zymes of glutaminase: glutaminase 
1 (GLS1) and glutaminase (GAC). 
We found decreased expression of 
GLS1 after treatment with com-
pound 968 in all three cell lines 
(Figure 1B). Given that GDH con-
verts glutamate to α-ketoglutarate 
in glutamine catabolism, we next 
examined if GDH activity was aff- 
ected after treatment with com-
pound 968 in HEY cells. Treatment 
with compound 968 significantly 
decreased the activity of GDH in the 
HEY cell line after 24 h treatment. 
These data suggest that compound 
968 has the ability to inhibit cell 
proliferation and reduce glutamine 
metabolism in ovarian cancer cells 
(Figure 1C). 
Compound 968 induced cell cycle 
G1 arrest
Studies indicate that glutamine is 
necessary for cell cycle progression 
[17]. We examined the effect of 
compound 968 on cell cycle pro-
gression in all three ovarian cancer 
cell lines and found that treatment 
with compound 968 for 48 h result-
ed in G1 phase cell cycle arrest. In 
addition to an increased proportion 
of cells in G1 phase, we noted a 
concomitant decreased proportion 
of cells in S phase (Figure 2A). 
Western blotting showed compound 
968 treatment caused reduced pro-
tein expression of CDK4 and cyclin 
D1 with increased expression of 
p21 and p27 (Figure 2B). These 
results are consistent with the 
effects of glutamine metabolism on 
cell cycle changes.
Compound 968 induced cell stress 
Figure 1. Compound 968 inhibited ovarian cancer cells proliferation. 
The ovarian cancer cell lines, HEY, SKOV3 and IGROV-1, were treated 
in DMEM/F12 medium containing 2.5 mM L-Glutamine and supplied 
with varying concentrations of compound 968 (0, 2, 5, 10, 25, 50 uM) 
for 5 days. Cell proliferation was assessed by MTT assay. Compound 
968 inhibited cell proliferation in a dose dependent manner (A). Com-
pound 968 reduced GLS1 (KGA and GAC) expression after 24 h treat-
ment (B). HEY cells were treated with compound 968 for 24 h, GDH 
activity was measured by ELISA assay (C) (*P<0.05). Data are shown 
as mean + SEM of three experiments. 
Given that glutamine metabolism is involved in 
modulating reduction-oxidation homeostasis 
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Figure 2. Compound 968 caused cell cycle G1 phase arrest. The HEY, SKOV3 and IGROV-1 ovarian cancer cell lines were treated with compound 968 at different 
concentrations for 48 h. Cell cycle analysis was performed using Cellometer. Treatment with compound 968 caused G1 phase cell cycle arrest in all three ovarian 
cancer cell lines (A). Cells were treated with various concentrations of compound 968 for 24 h, Western blotting showed compound 968 decreased cyclin D1 and 
CDK4 expression and increased p21 and p 27 expression in all three cell lines (B). Data are shown as mean + SEM of two experiments (*P<0.05).
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and oxidative stress [4, 10], we tested the 
effects of compound 968 on the production of 
intracellular reactive oxygen species (ROS) and 
protein expression of endoplasmic reticulum 
stress. We treated all three ovarian cancer cell 
lines with compound 968 for 24 h. We found 
that treatment with compound 968 signifi- 
cantly increased ROS production in a dose 
dependent manner (Figure 3A). Western blot-
ting showed the protein expression of prot- 
ein kinase-like endoplasmic reticulum kinase 
(PERK), calnexin and binding immunoglobulin 
protein (BiP) increased after treatment with 
compound 968 (Figure 3B), suggesting that 
compound 968 induces significant cellular 
stress in ovarian cancer cells. 
Compound 968 induced cell apoptosis
The effect of compound 968 on apoptosis was 
evaluated in all three ovarian cancer cells. We 
treated the cell lines with varying concentra-
tions of compound 968 for 60 h, and found sig-
nificantly increased expression of Annexin V 
with increasing concentrations of compound 
968 (Figure 4A). We performed western blot-
ting and found decreased expression of MCL-1, 
a member of the Bcl-2 family, after 24 h treat-
ment with compound 968 (Figure 4B). These 
results demonstrate that treatment with com-
pound 968 results in increased apoptosis in 
ovarian cancer cell lines.
Compound 968 sensitized paclitaxel in ovarian 
cancer cells
Inhibition of glutaminolysis has been previously 
shown to sensitize paclitaxel in paclitaxel-resis-
tant breast cancer cells [18]. We assessed the 
effect of glutamine and compound 968 on sen-
sitivity to paclitaxel in ovarian cancer cell lines. 
As expected, increasing glutamine concentra-
tions resulted in increased cell proliferation 
and decreased cell sensitivity to low dose pacli-
taxel in all three ovarian cancer cell lines (Figure 
5A). MTT assays demonstrated that the combi-
nation of 5 uM of compound 968 with paclitax-
el at varying concentrations resulted in syner-
gistic inhibitory effects in all three ovarian can-
cer cell lines after 72 h treatment (Figure 5B, 
CI<1). These results suggest that compound 
968 treatment increased the sensitivity of the 
ovarian cancer cells to paclitaxel.
Figure 3. Treatment of Compound 968 caused cellular stress. Compound 968 induced intracellular reactive oxygen 
species (ROS) production in a dose dependent manner after 24 h treatment in all three ovarian cancer cell lines (A). 
HEY, SKOV3 and IGROV-1 cells were treated with compound 968 for 24 h. Western blotting found that compound 
968 induced the expression of PERK, calnexin and BiP (B). Data are shown as mean + SEM of two experiments. 
(*P<0.05).
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Figure 4. Treatment of Compound 968 
induced significant cell apoptosis. 
Cells were treated with compound 968 
for 60 h. Apoptosis was detected using 
Annexin-V FITC assay. Compound 968 
increased Annexin V expression in all 
three cell lines (A). Western blotting in-
dicated treatment with compound 968 
for 24 h decreased the expression of 
the anti-apoptotic protein, MCL-1 (B). 
Data are shown as mean + SEM of two 
experiments (*P<0.05).
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Figure 5. Compound 968 sensitized paclitaxel in ovarian cancer cells. The cells were treated with different concentrations of paclitaxel (0, 0.1, 1.0, 10, 50 nM) in 
media with various concentrations of glutamine for 72 h. MTT assays showed that deprivation of glutamine or low concentrations of glutamine increased sensitivity 
to paclitaxel (A). The cells were treated with 5 compound 968 in combination with different concentrations of paclitaxel for 48 h. Compound 968 synergized with the 
anti-proliferative effects of paclitaxel in the ovarian cancer cell lines (B, CI<1). Data are shown as mean + SEM of three experiments (*P<0.05).
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Discussion 
We found that compound 968 inhibits cell pro-
liferation, induces G1 phase cell cycle arrest, 
and initiates apoptotic cell death in the HEY, 
SKOV3 and IGROV-1 ovarian cancer cell lines in 
a dose dependent manner. Increased ROS pro-
duction was also seen with increasing doses of 
compound 968. Moreover, low concentrations 
of glutamine resulted in increased sensitivity of 
ovarian cancer cells to paclitaxel, while com-
pound 968 treatment resulted in significant 
synergy when combined with paclitaxel to inhib-
it ovarian cancer cell growth. These results sup-
port a role for targeting GLS1 or inhibiting gluta-
mine metabolism as a valuable strategy for the 
treatment of ovarian cancer [6, 10, 13].
Glutamine is a major source of carbon and 
energy to promote cell growth and viability in 
cancer. The activity of glutaminase (GLS) and 
glutamine levels correlate with cancer cell pro-
liferation in vitro [19]. High level of GLS1 pro-
tein expression is associated with worse overall 
survival in patients with ovarian cancer and 
silencing of GLS1 via siRNA in glutamine depen-
dent SKOV3 cell-bearing mice results in a sig-
nificant reduction in tumor weight and tumor 
volume when compared to controls [20]. The 
depletion of glutamine results in inhibition of 
cell proliferation, induction of G1 phase cell 
cycle arrest, and apoptosis through mTOR/S6 
pathway in ovarian cancer cells. GLS knock-
down results in reduced mitochondrial mem-
brane potential in glioma cells, suggesting that 
mitochondrial dysfunction plays a role in induc-
ing apoptosis with inactivity of GLS [21]. Recent 
studies indicate that the response to glutamine 
deprivation in cancer cells is dependent on 
their different genetic and epigenetic back-
ground [9, 13]. 
The mechanisms of action of compound 968’s 
inhibition on cancer cell proliferation are less 
well characterized. Treatment of MDA-MB-231 
cells with compound 968 resulted in downr- 
egulation of 11 anti-apoptotic genes, upregu- 
lation of several critical tumor suppressor 
genes (including VHL, MGMT and FHIT), and 
alternations of the expression for genes rela- 
ted to cell cycle progression, suggesting that 
inhibition of cell growth by compound 968 
was related to induction of apoptosis and cell 
cycle arrest in breast cancer cells. These chan- 
ges in gene expression were accompanied by 
an increase in histone H4K16ac and a decrease 
in H3K4me3 suggesting that altered regulation 
of cell cycle progression through histone modi-
fications may also play a role [13, 22, 23]. In 
this study, we evaluated the impact of com-
pound 968 on cell cycle arrest and apoptosis 
in three ovarian cancer cell lines. Our results 
show that compound 968 inhibited cell growth 
through induction of G1 phase cell cycle arrest 
and augmented Annexin-V expression, along 
with decreased expression of CDK4, cyclin D1 
and MCL-1, and increased p21 and p27 expres-
sion in all three cell lines. These results are 
consistent with experiments showing depriva-
tion of glutamine causes apoptosis and cell 
cycle arrest in some types of cancer [10, 
24-26]. 
Deprivation of glutamine in cell culture can 
increase ROS production and induce endop- 
lasmic reticulum stress [10]. Glutamine met- 
abolism protects against oxidative stress by 
increasing reduced glutathione (GSH) levels, 
an antioxidant, and providing a source of 
nico-tinamide adenine dinucleotide phosphate 
(NADPH) [27]. Depletion of GLS1 by shRNA 
exhibited lower levels of both GSH and oxidi- 
zed glutathione (GSSG) [21], indicating that 
GLS1 activity was involved in the process of 
oxidative stress. Treatment with BPTES, an 
allosteric inhibitor of glutaminase, in lung can-
cer cells resulted in increased ROS levels 
through inhibition of glucose flow into the 
Kreb’s cycle and reduced oxidative phospho- 
rylation in the mitochondria [28]. In agree- 
ment with our previous study of glutamine 
metabolism in ovarian cancer, we found that 
compound 968 at varying concentrations led 
to decreased GLS1 expression and increased 
ROS production in a dose dependent manner 
with accompanied increased expression of 
ER stress markers including Calnexin, BiP and 
PERK. These changes ultimately culminated 
in cell death and decreased proliferation in 
all three ovarian cancer cell lines evaluated. 
Recent studies have implicated that histone 
H4K16AC acetylation and histone acetyltr- 
ansferase, Mof, are associated with oxidative 
stress induced by hydrogen peroxide and that 
H4K16AC regulates the expression of the ROS-
generating enzyme, NADPH oxidase 4 (Nox4) 
[29, 30]. Given that treatment with compound 
968 increased H4K16AC level in breast cancer 
cells, we postulate that epigenetic regulation 
was involved in the cellular stress process 
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induced by compound 968. The complexity of 
cellular oxidative stress and endoplasmic reti- 
culum stress and the exact mechanisms by 
which compound 968 induces both stresses 
provide opportunities for further investigation. 
Hence, in combination with the above results, 
we believe compound 968 inhibits cell prolifer-
ation through multiple pathways including ROS 
formation, cell cycle arrest and apoptosis. 
Paclitaxel is a standard chemotherapeutic 
agent for the treatment of ovarian cancer. It 
has been reported that paclitaxel can increase 
glutamine uptake and GLS1 expression in 
breast cancer cells. High expression of GLS1 
and upregulation of glutamine metabolism 
are associated with paclitaxel resistant breast 
cancer cells and knockdown of GLS1 by siRNA 
results in sensitization of paclitaxel-resistant 
breast cancer cells to paclitaxel [18]. Gluta- 
mine deprivation creates synthetic lethality 
to paclitaxel in breast and prostate cell lines 
bearing K-Ras-mutations [26]. Targeting GLS1 
by CB-839, a novel selective glutaminase in- 
hibitor, significantly inhibited tumor cell growth 
in vitro and in vivo [25, 31, 32]. CB-839 in com-
bination with paclitaxel largely increased the 
sensitivity to paclitaxel in xenograft models of 
triple-negative breast cancer [31]. After treat-
ing the ovarian cancer cell lines with different 
concentrations of glutamine in combination 
with paclitaxel, we observed that low concen-
trations or depletion of glutamine considerably 
increased the sensitivity of the cells to low 
doses of paclitaxel in all three cell lines. We 
also found that the combination of compound 
968 and paclitaxel significantly and synergisti-
cally increased the sensitivity of the ovarian 
cancer cell lines to paclitaxel. Together, our 
results indicate that glutaminase appears to be 
a promising therapeutic target for ovarian can-
cer and worthy of further investigation.
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